Whole exome sequencing in a random sample of north American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  McGuire, Megan M ^a   Yatsenko, Alexander ^a   Hoffner, Lori ^a   Jones, Mirka ^b   Surti, Urvashi ^a   Rajkovic, Aleksandar ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; MED12 PROTEIN, HUMAN; MEDIATOR COMPLEX;

ARTICLE; CARCINOGENESIS; CAUCASIAN; CODON; EXOME; EXON; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MED12 GENE; MISSENSE MUTATION; NEGRO; NORTH AMERICA; SINGLE NUCLEOTIDE POLYMORPHISM; UTERUS MYOMA; DNA SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; LEIOMYOMATOSIS; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; UTERUS CANCER;

BASE SEQUENCE; DNA, COMPLEMENTARY; EXOME; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEIOMYOMATOSIS; MEDIATOR COMPLEX; MOLECULAR SEQUENCE DATA; MUTATION; NORTH AMERICA; SEQUENCE ANALYSIS, DNA; UTERINE NEOPLASMS;

EID: 84858054364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033251     Document Type: Article

References (26)

1. Hashimoto K, Azuma C, Kamiura S, Kimura T, Nobunaga T, et al. (1995) Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 40: 204-208.
2. Cramer SF, Patel A, (1990) The frequency of uterine leiomyomas. Am J Clin Pathol 94: 435-438.
3. Flake GP, Andersen J, Dixon D, (2003) Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111: 1037-1054.
4. Guarnaccia MM, Rein MS, (2001) Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol 44: 385-400.
5. Bowden W, Skorupski J, Kovanci E, Rajkovic A, (2009) Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays. Mol Hum Reprod 15: 563-568.
6. Ishwad CS, Ferrell RE, Hanley K, Davare J, Meloni AM, et al. (1997) Two discrete regions of deletion at 7q in uterine leiomyomas. Genes Chromosomes Cancer 19: 156-160.
7. Brosens I, Deprest J, Dal Cin P, Van den Berghe H, (1998) Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 69: 232-235.
8. Nilbert M, Heim S, Mandahl N, Floderus UM, Willen H, et al. (1990) Trisomy 12 in uterine leiomyomas. A new cytogenetic subgroup. Cancer Genet Cytogenet 45: 63-66.
9. Hug K, Doney MK, Tyler MJ, Grundy DA, Soukup S, et al. (1994) Physical mapping of the uterine leiomyoma t(12;14)(q13-15;q24.1) breakpoint on chromosome 14 between SPTB and D14S77. Genes Chromosomes Cancer 11: 263-266.
10. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, et al. (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30: 406-410.
11. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, et al. (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43: 18-27.
12. Lehtonen R, Kiuru M, Vanharanta S, Sjoberg J, Aaltonen LM, et al. (2004) Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 164: 17-22.
13. Lyon MF, (1999) X-chromosome inactivation. Curr Biol 9: R235-237.
14. Nilbert M, Heim S, (1990) Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 2: 3-13.
15. Rein MS, Friedman AJ, Barbieri RL, Pavelka K, Fletcher JA, et al. (1991) Cytogenetic abnormalities in uterine leiomyomata. Obstet Gynecol 77: 923-926.
16. Canevari RA, Pontes A, Rosa FE, Rainho CA, Rogatto SR, (2005) Independent clonal origin of multiple uterine leiomyomas that was determined by X chromosome inactivation and microsatellite analysis. Am J Obstet Gynecol 193: 1395-1403.
17. Malik S, Roeder RG, (2005) Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends Biochem Sci 30: 256-263.
18. Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ, (2009) The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol 29: 650-661.
19. Rickert P, Corden JL, Lees E, (1999) Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 18: 1093-1102.
20. Malumbres M, (2011) Physiological relevance of cell cycle kinases. Physiol Rev 91: 973-1007.
21. Rocha PP, Scholze M, Bleiss W, Schrewe H, (2010) Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development 137: 2723-2731.
22. Risheg H, Graham JM Jr, Clark RD, Rogers RC, Opitz JM, et al. (2007) A recurrent mutation in MED12 leading to R961W causes Opitz-Kaveggia syndrome. Nat Genet 39: 451-453.
23. Schwartz CE, Tarpey PS, Lubs HA, Verloes A, May MM, et al. (2007) The original Lujan syndrome family has a novel missense mutation (p.N1007S) in the MED12 gene. J Med Genet 44: 472-477.
24. Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, et al. (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334: 252-255.
25. Makinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, et al. (2011) MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2: 966-969.
26. Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, et al. (2012) MED12 mutations in uterine fibroids- their relationship to cytogenetic subgroups. Int J Cancer.